Torsemide
As of the edition of 20 October 2026, Torsemide is a small molecule: marketed, first approved in 1993 (US); acts on SLC12A1; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2005
- Kind
- Small molecule
- Brand name
- Demadex
- First approved
- 23 August 1993 (US)
- Approvals on record
- 11 in 3 regions
- Holder of the most recent approval
- Sarfez Pharmaceuticals; 5 holders in all
- Registered trials
- 28, 3 stopped early
- Disease areas
- Heart and blood vessels; Inherited and neonatal; Pregnancy and women's health; Urinary and reproductive; Nutrition and metabolism; Hormones
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Torsemide.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SLC12A1 | Solute carrier family 12 member 1 | Q13621 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 5 | 2 | 0 | 0 |
| Phase 1 | 11 | 9 | 1 | 1 |
| Phase 2 | 3 | 2 | 0 | 1 |
| Phase 3 | 2 | 2 | 0 | 0 |
| Phase 4 | 7 | 3 | 0 | 1 |
| All trials | 28 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Roche | Applicant and Earlier holder | 1993 to now |
| Sarfez Pharmaceuticals | Later holder and Lead sponsor of trials | 2017 to now |
| Pharmobedient Consulting | Acquired holder | 2025 to now |